Clayton Financial Group’s Moderna MRNA Stock Holding History

Clayton Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21	Closed	-$1.07K	–	388
2026 Q1	$1.07K	Hold	21	–	–	﹤0.01%	559
2025 Q4	$620	Buy	+21	New	+$571	﹤0.01%	578

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Clayton Financial Group's MRNA Position: Q2 2026 in Review

Clayton Financial Group sold out of Moderna (MRNA) in Q2 2026, closing a stake of 21 shares — an estimated $1.07K sold.

Clayton Financial Group first reported a position in MRNA in Q4 2025 and held it in 2 quarters. The position peaked at $1.07K in Q1 2026. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Clayton Financial Group reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Clayton Financial Group sold 21 Moderna shares in Q2 2026, an estimated $1.07K.
Clayton Financial Group first reported a position in Moderna in Q4 2025 and held it in 2 quarters.
Clayton Financial Group's Moderna position peaked at $1.07K in Q1 2026.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Clayton Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.